# An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

> **NCT00247676** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 37 (actual)

## Conditions studied

- Liver Neoplasms
- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sunitinib (SU011248)

## Key facts

- **NCT ID:** NCT00247676
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-02
- **Final completion:** 2009-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2010-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00247676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00247676, "An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00247676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*